Print

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)

https://www.facingourrisk.org/research-clinical-trials/study/115/tucatinib-plus-trastuzumab-in-patients-with-her2-colorectal-cancer-mountaineer

Clinicaltrials.gov identifier:
NCT03043313 (https://clinicaltrials.gov/show/NCT03043313)

Treatment

Study Contact Information:

For more information, contact Seagen Trial Information Support at 866-333-7436 or by email. 

About the Study

This is a study for people who have been diagnosed with HER2-positive (HER2+) metastatic colorectal cancer (mCRC).  The goal of this study is to look at how well the drug tucatinib (Tukysa) works to improve outcomes when given with trastuzumab (Herceptin), versus how well tucatinib works when administered by itself. NOTE: This study is no longer enrolling patients. 

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is Not Open To:

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.